Last updated: August 18, 2026

Examiner: O'BRIEN, LEA S

Tech Center 1600 • Art Units: 1644 1646

This examiner grants 51% of resolved cases

Performance Statistics

51.4%

Allow Rate

-8.6% vs TC avg

Total Applications

+13.9%

Interview Lift

1220

Avg Prosecution Days

Based on 35 resolved cases, 2023–2026

5.1%

§101 Eligibility

11.2%

§102 Novelty

32.1%

§103 Obviousness

25.0%

§112 Clarity

App #	Title	Status	Assignee
18575949	PERSONALIZED VACCINE ADMINISTRATION	Non-Final OA	Daicel Corporation
17907036	TRANSFERRIN RECEPTOR 1 TARGETING FOR CARCINOGENESIS PREVENTION	Final Rejection	The Regents of the University of California
17762685	NOTCH RECEPTORS WITH MINIMAL LINKER	Final Rejection	The Regents of the University of California
18338985	METHODS FOR TREATMENT OF PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA WITH MOSUNETUZUMAB AND LENALIDOMIDE	Non-Final OA	Hoffmann-La Roche Inc.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.